These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 8795576)

  • 1. Generation of chimeric bispecific G250/anti-CD3 monoclonal antibody, a tool to combat renal cell carcinoma.
    Luiten RM; Coney LR; Fleuren GJ; Warnaar SO; Litvinov SV
    Br J Cancer; 1996 Sep; 74(5):735-44. PubMed ID: 8795576
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Localization of monoclonal antibody G250 and bispecific monoclonal antibody CD3/G250 in human renal-cell carcinoma xenografts: relative effects of size and affinity.
    van Dijk J; Zegveld ST; Fleuren GJ; Warnaar SO
    Int J Cancer; 1991 Jul; 48(5):738-43. PubMed ID: 1830033
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chimeric bispecific OC/TR monoclonal antibody mediates lysis of tumor cells expressing the folate-binding protein (MOv18) and displays decreased immunogenicity in patients.
    Luiten RM; Warnaar SO; Sanborn D; Lamers CH; Bolhuis RL; Litvinov SV; Zurawski VR; Coney LR
    J Immunother; 1997 Nov; 20(6):496-504. PubMed ID: 9409456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chimeric scFv/gamma receptor-mediated T-cell lysis of tumor cells is coregulated by adhesion and accessory molecules.
    Weijtens ME; Willemsen RA; van Krimpen BA; Bolhuis RL
    Int J Cancer; 1998 Jul; 77(2):181-7. PubMed ID: 9650549
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of tumor-cell lysis by bi-specific monoclonal antibodies recognizing renal-cell carcinoma and CD3 antigen.
    van Dijk J; Warnaar SO; van Eendenburg JD; Thienpont M; Braakman E; Boot JH; Fleuren GJ; Bolhuis RL
    Int J Cancer; 1989 Feb; 43(2):344-9. PubMed ID: 2521843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-renal-cell carcinoma chimeric antibody G250 facilitates antibody-dependent cellular cytotoxicity with in vitro and in vivo interleukin-2-activated effectors.
    Surfus JE; Hank JA; Oosterwijk E; Welt S; Lindstrom MJ; Albertini MR; Schiller JH; Sondel PM
    J Immunother Emphasis Tumor Immunol; 1996 May; 19(3):184-91. PubMed ID: 8811493
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor.
    Tso CL; Zisman A; Pantuck A; Calilliw R; Hernandez JM; Paik S; Nguyen D; Gitlitz B; Shintaku PI; de Kernion J; Figlin R; Belldegrun A
    Cancer Res; 2001 Nov; 61(21):7925-33. PubMed ID: 11691814
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhancement of the lytic activity of cloned human CD8 tumour-infiltrating lymphocytes by bispecific monoclonal antibodies.
    Gorter A; Krüse KM; Schrier PI; Fleuren GJ; van de Griend RJ
    Clin Exp Immunol; 1992 Jan; 87(1):111-6. PubMed ID: 1531120
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficiency of T cell triggering by anti-CD3 monoclonal antibodies (mAb) with potential usefulness in bispecific mAb generation.
    Jacobs N; Mazzoni A; Mezzanzanica D; Negri DR; Valota O; Colnaghi MI; Moutschen MP; Boniver J; Canevari S
    Cancer Immunol Immunother; 1997 Jul; 44(5):257-64. PubMed ID: 9247560
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A bispecific monoclonal antibody directed against both the membrane-bound complement regulator CD55 and the renal tumor-associated antigen G250 enhances C3 deposition and tumor cell lysis by complement.
    Blok VT; Daha MR; Tijsma O; Harris CL; Morgan BP; Fleuren GJ; Gorter A
    J Immunol; 1998 Apr; 160(7):3437-43. PubMed ID: 9531304
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beta-glucan enhanced killing of renal cell carcinoma micrometastases by monoclonal antibody G250 directed complement activation.
    Sier CF; Gelderman KA; Prins FA; Gorter A
    Int J Cancer; 2004 May; 109(6):900-8. PubMed ID: 15027124
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epidermal growth factor receptor and g250: useful target antigens for antibody mediated cellular cytotoxicity against renal cell carcinoma?
    Stadick H; Stockmeyer B; Kühn R; Schrott KM; Kalden JR; Glennie MJ; van de Winkel JG; Gramatzki M; Valerius T; Elsässer D
    J Urol; 2002 Feb; 167(2 Pt 1):707-12. PubMed ID: 11792958
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-renal cell carcinoma chimeric antibody G250: cytokine enhancement of in vitro antibody-dependent cellular cytotoxicity.
    Liu Z; Smyth FE; Renner C; Lee FT; Oosterwijk E; Scott AM
    Cancer Immunol Immunother; 2002 May; 51(3):171-7. PubMed ID: 11941456
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New chimeric anti-pancarcinoma monoclonal antibody with superior cytotoxicity-mediating potency.
    Velders MP; Litvinov SV; Warnaar SO; Gorter A; Fleuren GJ; Zurawski VR; Coney LR
    Cancer Res; 1994 Apr; 54(7):1753-9. PubMed ID: 8137290
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of bispecific monoclonal antibody (bsAb)-targeted cytolysis by human anti-mouse antibodies in ovarian carcinoma patients treated with bsAb-targeted activated T-lymphocytes.
    Lamers CH; Gratama JW; Warnaar SO; Stoter G; Bolhuis RL
    Int J Cancer; 1995 Feb; 60(4):450-7. PubMed ID: 7829257
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunohistochemical analysis of tumor antigen saturation following injection of monoclonal antibody G250.
    Steffens MG; Oosterwijk-Wakka JC; Zegwaart-Hagemeier NE; Boerman OC; Debruyne FM; Corstens FH; Oosterwijk E
    Anticancer Res; 1999; 19(2A):1197-200. PubMed ID: 10368675
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and characterization of anti-renal cell carcinoma x antichelate bispecific monoclonal antibodies for two-phase targeting of renal cell carcinoma.
    Kranenborg MH; Boerman OC; Oosterwijk-Wakka JC; de Weijert MC; Corstens FH; Oosterwijk E
    Cancer Res; 1995 Dec; 55(23 Suppl):5864s-5867s. PubMed ID: 7493361
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of the CD4+ and CD8+ tumor infiltrating lymphocytes propagated with bispecific monoclonal antibodies.
    Wong JT; Pinto CE; Gifford JD; Kurnick JT; Kradin RL
    J Immunol; 1989 Nov; 143(10):3404-11. PubMed ID: 2509557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heteroconjugate antibody-directed killing of autologous human renal carcinoma cells by in vitro-activated lymphocytes.
    Kerr L; Huntoon C; Donohue J; Leibson PJ; Bander NH; Ghose T; Luner SJ; Vessella R; McKean DJ
    J Immunol; 1990 May; 144(10):4060-7. PubMed ID: 2139677
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phenotype, cytokine production and cytolytic capacity of fresh (uncultured) tumour-infiltrating T lymphocytes in human renal cell carcinoma.
    Van den Hove LE; Van Gool SW; Van Poppel H; Baert L; Coorevits L; Van Damme B; Ceuppens JL
    Clin Exp Immunol; 1997 Sep; 109(3):501-9. PubMed ID: 9328129
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.